Asset Details
Do you wish to reserve the book?
Development and validation of the Chiari-like malformation and syringomyelia evaluation: the CHASE questionnaire
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development and validation of the Chiari-like malformation and syringomyelia evaluation: the CHASE questionnaire
Do you wish to request the book?
Development and validation of the Chiari-like malformation and syringomyelia evaluation: the CHASE questionnaire
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development and validation of the Chiari-like malformation and syringomyelia evaluation: the CHASE questionnaire
2026
Overview
Abstract
Background
Chiari-like malformation (CM) and syringomyelia (SM) in dogs are associated with signs of neuropathic pain and itch, which are difficult to quantify reliably.
Hypothesis/Objectives
Develop and validate the Chiari-like malformation and syringomyelia evaluation (CHASE) questionnaire to quantify owners’ assessments of clinical signs of CM/SM in their dogs.
Animals
Twenty client-owned healthy dogs and 30 CM/SM affected dogs.
Methods
The CHASE questionnaire was developed using an iterative sampling design, reliability and normal scores were established in healthy dogs. A double-blinded, randomized, crossover study design was conducted using pregabalin and placebo, with CHASE as the primary outcome. Physical and neurologic examinations, activity monitors, quantitative sensory testing (QST), and quality of life assessments (QOL) were performed alongside the CHASE questionnaire at each time point.
Results
Baseline CHASE scores were significantly higher in CM/SM dogs compared with healthy dogs (15.3 ± 4.8 vs. 1.4 ± 1.8; P < .01), with score ranges of 6-24 and 0-6, respectively. The CHASE scores in CM/SM dogs were moderately repeatable from screening (15.1 ± 4.4) to baseline (15.1 ± 4.7) and decreased significantly with pregabalin compared with baseline and placebo (P < 0.001 and P < 0.03). The questionnaire had strong internal consistency (α = 0.89) and differentiated pregabalin from placebo with 63% sensitivity and 76% specificity (area under the curve = 0.67). No significant differences in QOL, QST, or activity levels were identified.
Conclusions and clinical importance
We validated the use of the CHASE questionnaire to quantify clinical signs associated with CM/SM and distinguish treatment outcomes when other assessments failed.
Publisher
Oxford University Press
Subject
